MammaPrint and BluePrint identify critical aspects of tumor biology in African-Americ

[News]

Agendia, Inc., a world leader in precision oncology, today announced the presentation of study results for BluePrint and MammaPrint use in identifying African-American women with hormone receptor positive tumors that have different genomic subtypes and risk than Caucasian women.

More... (https://www.news-medical.net/news/20190604/MammaPrint-and-BluePrint-identify-critical-aspects-of-tumor-biology-in-African-American-breast-cancer-patients.aspx)